Literature DB >> 6431262

Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain fatty acids.

B J Perlman, D B Goldstein.   

Abstract

The cell membrane-disordering potencies of sodium valproate, the sodium salts of other short-chain fatty acids, and ethanol were compared using fluorescence polarization with the probe 1,6-diphenyl-1,3,5-hexatriene. Valproate was about 7 times more potent in fluidizing synaptosomal plasma membranes than ethanol, a prototypic disordering agent. The disordering potency of the straight-chain fatty acids pentanoate through octanoate increased by a factor of 2.2 with each additional methylene group. The sedative potencies of the drugs were assessed by determining the brain concentration at which Swiss Webster mice lost the ability to balance on a stationary wooden dowel. Relative anticonvulsant potency was measured by determining the ED50 for protection against pentylenetetrazol-induced seizures and then determining the brain levels of drug that were actually achieved at the time of seizure protection. The ability of the fatty acids and ethanol to disorder membranes in vitro correlated closely with their ability to cause sedation and protect mice against pentylenetetrazol-induced seizures. These data suggest that valproic acid might exert some of its effects by disordering brain cell membranes--the proposed mechanism of action of ethanol and the general anesthetics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6431262

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Ultrastructure of Purkinje cell perikarya and their dendritic processes in the rat cerebellar cortex in experimental encephalopathy induced by chronic application of valproate.

Authors:  M E Sobaniec-Lotowska
Journal:  Int J Exp Pathol       Date:  2001-12       Impact factor: 1.925

2.  Phosphatidylserine dictates the assembly and dynamics of caveolae in the plasma membrane.

Authors:  Takashi Hirama; Raibatak Das; Yanbo Yang; Charles Ferguson; Amy Won; Christopher M Yip; Jason G Kay; Sergio Grinstein; Robert G Parton; Gregory D Fairn
Journal:  J Biol Chem       Date:  2017-07-11       Impact factor: 5.157

3.  Continuum solvent model studies of the interactions of an anticonvulsant drug with a lipid bilayer.

Authors:  A Kessel; B Musafia; N Ben-Tal
Journal:  Biophys J       Date:  2001-06       Impact factor: 4.033

4.  Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures.

Authors:  M Nilsson; E Hansson; L Rönnbäck
Journal:  Neurochem Res       Date:  1992-04       Impact factor: 3.996

5.  Absorption enhancement of rectally infused cefoxitin sodium by medium-chain fatty acids in conscious rats: concentration-effect relationship.

Authors:  E J van Hoogdalem; M A Hardens; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

6.  Metal ions affect neuronal membrane fluidity of rat cerebral cortex.

Authors:  S Ohba; M Hiramatsu; R Edamatsu; I Mori; A Mori
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

Review 7.  Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.

Authors:  W Löscher
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

Review 8.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

9.  Neurotoxicity of ammonia and fatty acids: differential inhibition of mitochondrial dehydrogenases by ammonia and fatty acyl coenzyme A derivatives.

Authors:  J C Lai; A J Cooper
Journal:  Neurochem Res       Date:  1991-07       Impact factor: 3.996

10.  Suppression of preoptic GABA release caused by push-pull-perfusion with sodium valproate.

Authors:  R Wolf; U Tscherne; H M Emrich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.